While several staff members are affected by the decision, there have been no admissions to the program to date, so no current students were affected.
“The University will make every effort to identify alternative positions throughout the institution in which affected faculty and staff might be retained,” said Kenneth Kaushansky, MD, Stony Brook University’s dean of the school of medicine and senior vice president of health studies. “I wish to thank all involved for the incredible hard work and effort that went into establishing this academic venture. Their efforts are truly appreciated.”
The university announced plans in February to enroll its first pharmacy-doctorate class in August.
More articles on pharmacy:
Rite Aid shakes up board after 2 failed mergers
Why patients may face longer waits for generics under North American trade proposal
Reversing course: GlaxoSmithKline will resume paying physicians who promote its drugs
